Stay updated with breaking news from Nasdaq Coll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday morning. COLL has been the subject of a number of other reports. Needham & Company LLC reiterated a buy rating and issued a $40.00 price target on shares of Collegium Pharmaceutical […]
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) will post its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect Collegium Pharmaceutical to post earnings of $1.37 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can […]
Values First Advisors Inc. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. Values […]
Values First Advisors Inc. trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. […]
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target […]